Keywords: Molecular Imaging, Cancer, BreastDeveloping new molecular targeted therapies for triple negative breast cancer remains an obstacle. MANCR is a long noncoding RNA overexpressed in TNBC that sustains aggressive breast cancer growth. Silencing its expression with siRNA nanoparticles suppresses tumor growth, and treatment efficacy can be assessed by MRMI with a targeted contrast agent, MT218. Reduction in contrast-to-noise ratio following treatment confirmed effectiveness of siRNA therapy and allowed regular monitoring of tumor inhibition. RNA therapy shows promise as a new approach for treating aggressive breast cancer, and MRMI with the targeted contrast agent is a non-invasive imaging tool for TNBC detection and therapeutic surveillance.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords